The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | The APOLLO trial: daratumumab for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, presents the results of the APOLLO Phase III randomized trial (NCT03180736), evaluating pomalidomide and dexamethasone (Pd) with or without subcutaneous (SC) daratumumab (dara), in patients with relapsed/refractory (R/R) multiple myeloma. SC daratumumab is associated with a significantly reduced risk of infusion-related reactions (IRRs) and a faster administration. The analysis found that progression-free survival (PFS), the primary endpoint of the study, was significantly prolonged in the dara-Pd arm compared to Pd alone. Complete- and very good partial-response rates were also substantially improved with the use of dara-Pd over Pd. The IRR rate with dara SC use was low and the safety profile of the triplet was consistent with that of established dara and Pd profiles. The trial is the first prospective trial where SC dara has been given in the context of another active treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Amgen, Bristol Myers Squibb, Takeda, BeiGene, Janssen
